Moreover, AML cell clones harboring mutant NRAS arise in some patients relapsing on targeted therapies, particularly FLT3 inhibition (crenolanib56 and gilteritinib57) and BCL2 inhibition in some cases (venetoclax58,59). This evidence concerns the gene FLT3 and acute myeloid leukemia.